Concentrated PRF

PreclinicalBiologic

IInonu University

Concentrated PRF is one of 35 biologic programs targeting Third Molar Surgery. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Third Molar SurgeryCompleted

Clinical TrialCompleted

Third Molar SurgeryPreclinical

Completed

Clinical TrialPreclinical

Completed

Competition

Competitive Landscape

127 competitors in Clinical Trial

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

3 2

Venclexta

AbbVie

Phase 3

2 3

Avelox

Bayer

Phase 3

2 4

Paraplatin

AAvyxa

Phase 3

2 5

Potassium Iodide

MMeda Pharmaceuticals

Phase 3

1 6

Opzelura

DDizal Pharmaceuticals

Phase 3

1 7

Ablysinol

CSL Behring

Phase 3

1 8

Nascobal

GGrupo Espanol de Tumores Neuroendocrinos

Phase 3

1 9

Buagafuran

BBeijing Union Pharmaceutical Factory Ltd

Phase 3

2 10

MCV4

CanSino Biologics Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Third Molar Surgery1 trial

Comparative Effects of CGF and PRP in Impacted Third Molar Surgery

Completed·RRecep Tayyip Erdogan University·N/A·NCT07320170·42 enrolled

Thin Gingival Biotype1 trial

Injectable Versus Concentrated Platelet-Rich Fibrin for Gingival Phenotype Modification: A Randomized Clinical Trial

Completed·IInonu University·Preclinical·NCT06964529·30 enrolled

Wound1 trial

Improving Palatal Donor Site Healing and Reducing Postoperative Morbidity With Concentrated Growth Factor and Collagen Fleece: Randomized Controlled Clinical Study

Completed·IInonu University·Preclinical·NCT07367165·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Concentrated PRF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Concentrated PRF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Concentrated PRF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Inonu University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: IInonu University

Concentrated PRF

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Third Molar Surgery1 trial

Thin Gingival Biotype1 trial

Wound1 trial

References

Drug Info

Quick Facts

Related News